DEVELOPMENT OF A BIOMARKER TEST FOR TIGIT IN A DIVERSE COHORT OF HUMAN PANCREATIC CANCER PATIENTS
By Madison George. Pancreatic ductal adenocarcinoma (PDAC) has a dismal 12% 5-year survival rate (SEER) due to a lack of early detection biomarkers and resistance to standard therapeutic options (surgery, chemotherapy, radiation).
Authors
- Philip A. Philip (ORCID: https://orcid.org/0000-0002-6513-3491)
- David Kwon (ORCID: https://orcid.org/0000-0003-2673-3758)
- Nina G. Steele (ORCID: https://orcid.org/0000-0003-1564-3562)
- Samuel D. Zwernik
- Simone Benitz (ORCID: https://orcid.org/0009-0005-9019-9176)
- Daniel James Salas-Escabillas (ORCID: https://orcid.org/0000-0002-0819-989X)
- Hakmin Park
- Hui-Ju Wen (ORCID: https://orcid.org/0009-0003-9253-3348)
- Rupen Shah (ORCID: https://orcid.org/0000-0002-8985-5237)
- Allison Wombwell
- Howard C. Crawford (ORCID: https://orcid.org/0000-0001-9360-3019)
- Daniel Long (ORCID: https://orcid.org/0000-0003-1887-2993)
- Gazala Khan (ORCID: https://orcid.org/0000-0001-6396-9511)
- Madison George (ORCID: https://orcid.org/0009-0006-2514-5371)
- Georges Nassif
- Kendyll Gartrelle (ORCID: https://orcid.org/0000-0002-2590-4028)
- Kailee M. Hartway
- Julie Clark
- Brian Theisen
Institutions
- Michigan State University (US)
Publication Details
- Journal
- Spartan Medical Research Journal
- Published
- 2024-08-30
- DOI
- https://doi.org/10.51894/001c.122822
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00